Literature DB >> 33030855

Understanding Gaps in the Hepatocellular Carcinoma Cascade of Care: Opportunities to Improve Hepatocellular Carcinoma Outcomes.

Robert J Wong1,2, Aijaz Ahmed1.   

Abstract

Hepatocellular carcinoma (HCC) is a leading cause of morbidity and mortality. Existing studies have highlighted significant disparities in HCC outcomes, particularly among vulnerable populations, including ethnic minorities, safety-net populations, underinsured patients, and those with low socioeconomic status and high risk behaviors. The majority of these studies have focused on HCC surveillance. Although HCC surveillance is one of the most important first steps in HCC monitoring and management, it is only one step in the complex HCC cascade of care that evolves from surveillance to diagnosis and tumor staging that leads to access to HCC therapies. In this current review, we explore the disparities that exist along this complex HCC cascade of care and further highlight potential interventions that have been implemented to improve HCC outcomes. These interventions focus on patient, provider, and system level factors and provide a potential framework for health systems to implement quality improvement initiatives to improve HCC monitoring and management.

Entities:  

Mesh:

Year:  2020        PMID: 33030855     DOI: 10.1097/MCG.0000000000001422

Source DB:  PubMed          Journal:  J Clin Gastroenterol        ISSN: 0192-0790            Impact factor:   3.062


  3 in total

1.  An Idealized Clinicogenomic Registry to Engage Underrepresented Populations Using Innovative Technology.

Authors:  Patrick Silva; Deborah Vollmer Dahlke; Matthew Lee Smith; Wendy Charles; Jorge Gomez; Marcia G Ory; Kenneth S Ramos
Journal:  J Pers Med       Date:  2022-04-29

2.  Clinical Study on Effect of Solution Focused Approach on the Complications, Pain, Sleep, and Quality of Life in Patients with Hepatocellular Carcinoma Undergoing TACE.

Authors:  Chunjie Ma; Yuexian Ma; Sidi Lu; Dan Li; Yan Wang; Yingxuan Xu; Tianyu Zhang; Youli Du; Lulu Wang
Journal:  Evid Based Complement Alternat Med       Date:  2021-09-15       Impact factor: 2.629

3.  Pan-cancer analysis identifies FAM49B as an immune-related prognostic maker for hepatocellular carcinoma.

Authors:  Feng Xu; Jionghuang Chen; Dihua Huang
Journal:  J Cancer       Date:  2022-01-01       Impact factor: 4.207

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.